Autolus Therapeutics (AUTL) Accumulated Expenses (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Accumulated Expenses for 9 consecutive years, with $55.8 million the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses rose 6.73% year-over-year to $55.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $55.8 million (up 6.73% YoY) and the FY2025 annual result came in at $55.8 million, up 6.73% from the prior year.
• Accumulated Expenses rose to $55.8 million in Q4 2025 per AUTL's latest filing, from $52.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for AUTL reached as high as $55.8 million in Q4 2025 and fell as low as $23.2 million in Q2 2021.
• A 5-year average of $37.5 million and a median of $35.1 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses fell 14.81% — and 2022, when it soared 72.38%.
• Year by year, Accumulated Expenses stood at $23.7 million in 2021, then surged by 72.38% to $40.8 million in 2022, then decreased by 2.98% to $39.6 million in 2023, then surged by 32.07% to $52.3 million in 2024, then increased by 6.73% to $55.8 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $55.8 million, $52.3 million, and $51.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.